ViroPharma's $4.2B deal is nothing to sneeze at
November 11, 2013 at 12:44 PM EST
Long before its focus on rare diseases fueled a $4.2 billion merger deal with Shire Pharmaceuticals, ViroPharma had a much simpler target for its first product...
